| Immune Response and Inflammation | Lifetime | 12 | NL 2 | 99.95 |
| Sepsis Diagnosis and Treatment | Lifetime | 6 | NL 1 | 99.96 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 8 | NL 2 | 99.83 |
| Pneumonia and Respiratory Infections | Lifetime | 25 | NL 1 | 99.81 |
| Inflammation biomarkers and pathways | Lifetime | 2 | NL 1 | 99.77 |
| Thermal Regulation in Medicine | Lifetime | 13 | NL 2 | 99.50 |
| S100 Proteins and Annexins | Lifetime | 28 | NL 1 | 99.36 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 129 | NL 11 | 99.55 |
| Respiratory Support and Mechanisms | Lifetime | 190 | NL 6 | 99.39 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 69 | NL 4 | 99.17 |
| Immune cells in cancer | Lifetime | 151 | NL 6 | 99.01 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 141 | NL 8 | 99.05 |
| Inflammasome and immune disorders | Lifetime | 109 | NL 6 | 98.61 |
| COVID-19 Clinical Research Studies | Lifetime | 514 | NL 13 | 98.02 |
| Neonatal Respiratory Health Research | Lifetime | 639 | NL 25 | 98.35 |
| Nosocomial Infections in ICU | Lifetime | 160 | NL 5 | 98.43 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 171 | NL 4 | 97.53 |
| Pediatric health and respiratory diseases | Lifetime | 371 | NL 19 | 97.59 |
| Bacterial Infections and Vaccines | Lifetime | 331 | NL 16 | 97.37 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 491 | NL 10 | 97.54 |
| Respiratory viral infections research | Lifetime | 715 | NL 25 | 97.63 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 396 | NL 22 | 96.88 |
| Burkholderia infections and melioidosis | Lifetime | 51 | NL 2 | 97.08 |
| Blood properties and coagulation | Lifetime | 394 | NL 18 | 96.41 |
| Adrenal Hormones and Disorders | Lifetime | 390 | NL 22 | 96.15 |
| Advanced Glycation End Products research | Lifetime | 400 | NL 10 | 95.16 |
| Blood disorders and treatments | Lifetime | 393 | NL 19 | 95.67 |
| Complement system in diseases | Lifetime | 487 | NL 20 | 95.99 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 956 | NL 19 | 95.56 |
| Chemokine receptors and signaling | Lifetime | 599 | NL 11 | 92.73 |
| Neonatal and Maternal Infections | Lifetime | 517 | NL 11 | 93.31 |
| Vagus Nerve Stimulation Research | Lifetime | 235 | NL 7 | 92.47 |
| Amoebic Infections and Treatments | Lifetime | 529 | NL 4 | 92.14 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 488 | NL 17 | 91.86 |
| Vitamin K Research Studies | Lifetime | 436 | NL 27 | 89.72 |
| Hemophilia Treatment and Research | Lifetime | 729 | NL 60 | 92.44 |
| Immune responses and vaccinations | Lifetime | 598 | NL 37 | 86.20 |
| Leptospirosis research and findings | Lifetime | 617 | NL 16 | 85.79 |
| Immune Response and Inflammation | 2021-2025 | 2 | NL 1 | 99.74 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 5 | NL 1 | 99.77 |
| Respiratory Support and Mechanisms | 2021-2025 | 454 | NL 26 | 95.17 |
| Nosocomial Infections in ICU | 2021-2025 | 105 | NL 3 | 92.37 |
| Inflammation biomarkers and pathways | 2021-2025 | 23 | NL 1 | 88.23 |
| Immune cells in cancer | 2021-2025 | 845 | NL 20 | 88.80 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 690 | NL 30 | 90.56 |
| Immune responses and vaccinations | 2021-2025 | 100 | NL 21 | 88.66 |
| Neonatal Respiratory Health Research | 2021-2025 | 909 | NL 41 | 90.99 |
| Pneumonia and Respiratory Infections | 2021-2025 | 570 | NL 26 | 90.71 |
| Inflammasome and immune disorders | 2021-2025 | 717 | NL 6 | 84.44 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 356 | NL 12 | 81.89 |
| Thermal Regulation in Medicine | 2021-2025 | 409 | NL 12 | 70.56 |
| Neonatal and Maternal Infections | 2021-2025 | 569 | NL 34 | 67.25 |
| Adrenal Hormones and Disorders | 2021-2025 | 745 | NL 21 | 68.69 |
| NF-κB Signaling Pathways | 2021-2025 | 830 | NL 3 | 32.93 |
